<DOC>
	<DOCNO>NCT00026156</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine follow docetaxel treating patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>S0027 : Vinorelbine Followed Docetaxel Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival patient advance non-small cell lung cancer either age 70 performance status 2 , treat sequential vinorelbine docetaxel . ( Age 70 old Zubrod 0-1 stratum close accrual 2/15/2003 . ) - Determine objective tumor response rate , include confirm unconfirmed complete partial , patient treat regimen . - Assess dose deliver report functional symptom status patient treat regimen . - Determine toxic effect regimen patient . - Determine feasibility perform pharmacokinetic study obtain pharmacokinetic data patient . OUTLINE : This multicenter study . Patients stratify accord age performance status ( age 70 Zubrod 0-1 v age 18 Zubrod 2 ) . ( Age 70 old Zubrod 0-1 stratum close accrual 2/15/2003 . ) Patients receive vinorelbine IV 6-10 minute day 1 8 . Treatment repeat every 21 day 3 course absence unacceptable toxicity . Beginning 2 week last dose vinorelbine , patient receive docetaxel IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day 3 course absence unacceptable toxicity . Quality life assess baseline , begin course 2-6 , week 22 . Patients follow week 22 , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A minimum 95 patient ( 55 patient age 70 Zubrod 0-1 40 patient age 18 Zubrod 2 ) accrue study within 12-18 month . ( Age 70 old Zubrod 0-1 stratum close accrual 2/15/2003 . )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm , newly diagnose , advanced primary nonsmall cell lung cancer ( NSCLC ) ( adenocarcinoma , large cell carcinoma , squamous cell carcinoma , unspecified ) , designate 1 follow stage : Selected stage IIIB ( exclude Pancoast tumor ) T4 lesion due malignant pleural effusion OR Multiple lesion single lobe contain T3 T4 primary Stage IV ( T , N , M1 ) Recurrent disease prior surgery and/or radiotherapy Measurable evaluable disease outside prior radiation port No bronchoalveolar carcinoma No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 ( age 70 ) ( Age 70 old Zubrod 01 stratum close accrual 2/15/2003 ) Zubrod 2 ( age 18 ) Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 2 time ULN alkaline phosphatase great ULN OR Alkaline phosphatase great 4 time ULN SGOT/SGPT great ULN Renal : Not specify Other : No prior severe hypersensitivity docetaxel drug formulate polysorbate 80 No grade 2 great sensory neuropathy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent biologic therapy NSCLC No concurrent filgrastim ( GCSF ) Chemotherapy : No prior systemic chemotherapy NSCLC Endocrine therapy : No prior concurrent hormonal therapy NSCLC Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Concurrent palliative radiotherapy smallfield nonmeasurable lesion ( i.e. , painful bony lesion ) allow No concurrent radiotherapy Surgery : See Disease Characteristics At least 3 week since prior thoracic major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>